Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jeffrey W. Clark"'
Autor:
Sai-Hong Ignatius Ou, David P. Carbone, Christina Siwak-Tapp, Mari Mino-Kenudson, Keith D. Wilner, Adriana Gonzalez, Haiquan Chen, Jeffrey W. Clark, Ryohei Katayama, Christine M. Lovly, A. John Iafrate, Alice T. Shaw, William Pao, Jeffrey A. Engelman, Eunice L. Kwak, Eugene J. Mark, Rong Fang, Kristin Bergethon, Nerina T. McDonald, Julie M. Batten, Hongbin Ji, Pierre P. Massion
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(8)
Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non–small-cell lung cancers (NSCLCs). Because little is known about these tumors, we examined the clinical characteristi
Autor:
Thomas A. Abrams, Jennifer A. Chan, David P. Ryan, Charles S. Fuchs, Brian M. Wolpin, Lawrence S. Blaszkowsky, Brittany Allen, Jeffrey W. Clark, Peter C. Enzinger, Aram F. Hezel, Jeffrey A. Meyerhardt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(2)
Purpose The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of this pathway has antitumor effects in preclinical studies. We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), a
Autor:
Jeffrey G. Supko, Jeffrey W. Clark, Moira Kirvan, Susan L. Connors, Thomas A. Puchalski, Barbara Rattner, Joann Proper, Rocio Garcia-Carbonero, C. Sidor, Joseph Paul Eder, Lowell E. Schnipper, Milos J. Janicek, William E. Fogler, David P. Ryan, Judah Folkman, Eric N. Phillips, Mary T. Keogan, Donald Kufe, Lawrence N. Shulman, Nancy M. Kinchla
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(18)
PURPOSE: To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in adult patients with refractory solid tumors. PATIENTS AND METHODS: The daily dose was
Autor:
Bruce A. Chabner, Jeffrey W. Clark
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13(9)
Autor:
D Coggin, Dan L. Longo, W J Urba, John W. Smith, Christoph Huber, William C. Kopp, Jeffrey W. Clark, Ronald G. Steis
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 9(10)
We conducted a phase I study in which an intramuscular injection of interferon gamma (IFN gamma) at 10, 50, or 100 micrograms/m2 was followed 5 minutes later by an intramuscular injection of 10, 50, or 100 micrograms/m2 of tumor necrosis factor-alfa
Autor:
John W. Smith, R L Miller, Jeffrey W. Clark, Ronald G. Steis, Louis A. VanderMolen, W J Urba, E D Crum, S K Beckner, Michael A. Bookman, J E McKnight
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 8(10)
Autologous lymphokine-activated killer (LAK) cells and recombinant human interleukin-2 (rIL-2) were administered intraperitoneally (IP) to 24 patients with malignancies limited to the peritoneal space. Ten patients had ovarian cancer, 12 had colorect
Autor:
Steven M. Larson, Michael A. Bookman, Richard P. McCabe, John W. Smith, Jeffrey W. Clark, Ronald G. Steis, James C. Reynolds, V Dailey, Jorge A. Carrasquillo, S. Del Vecchio
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 8(3)
Two human immunoglobulin M (IgM) monoclonal antibodies (MoAbs), 16.88 and 28A32, which react with cytoplasmic (28A32 and 16.88) or cell surface (28A32) determinants on human colon carcinoma cells, were administered intravenously to 26 patients with m